156 Pages | 49 Exhibits | 2011 Analysis | Forecasts Through 2015 Product Family: Market Reports

Incontinence may be defined as the involuntary loss of bladder or bowel control. In the United States (U.S.), urinary incontinence (UI) afflicts an estimated 50 million people. According to the National Association for Continence (NAFC), approximately 75% to 80% of the UI population are women, with 9 million to 13 million suffering severe symptoms.

Although UI is an extremely common problem, and has a significant impact on quality of life, the vast majority of those who experience the condition do not undergo treatment, in part due to cost, embarrassment, or fear of risky surgical procedures. There is therefore a very strong demand for less costly, less invasive and more tolerable, discreet, nonsurgical UI therapies.

While current economic conditions and other factors continue to restrain market growth, the market for minimally invasive UI therapy systems is expected to exhibit relatively strong growth over the next 5 years. Valued at more than $190 million in 2010, the U.S. Minimally Invasive Urinary Incontinence Therapy Systems market is expected to increase at a healthy compound annual rate of 2.7%, with sales reaching more than $220 million in 2015. The market is expected to benefit not only from strong demand but from highly positive demographic trends, including a large, growing UI population and limited options for truly effective therapeutic alternatives.

This dynamic report from Medtech Insight includes analyses of products, markets, competitors, and emerging technology and opportunities. Covered topics in this report include injectable urethral bulking agents; urethral sling systems; implantable sacral nerve neurostimulators; nonsurgical office-based neuromodulation/percutaneous tibial nerve stimulation; and other nonsurgical treatments.


ii. Stress Urinary Incontinence 
iii. Overactive Bladder and Urge Incontinence 
iv. Treatment 
	a. Prescription Drug Therapy 
	b. Botulinum Toxin 
	c. Bulking Agents 
	d. Implantable Neurostimulation 
	e. Percutaneous Tibial Nerve Stimulation 
	f. Urethral Slings 
	g. Surgical Options 
v. Minimally Invasive Urinary Incontinence Therapy Systems Market 
	a. Procedure Volumes 
	b. Market Forecast 
vi. Methodology 

Exhibit ES-1: Minimally Invasive Urinary Incontinence Therapy, Procedure Volumes Forecast, 2010-2015 
Exhibit ES-2: Minimally Invasive Urinary Incontinence Therapy Systems, Market Forecast, 2010-2015 


1.1 Anatomy of the Urinary System 
1.2 Types of Urinary Incontinence 
	1.2.1 Stress Urinary Incontinence Causes
	1.2.2 Overactive Bladder and Urge Incontinence Causes 
1.3 Treatment 
	1.3.1 Prescription Drug Therapy 
	1.3.2 Botulinum Toxin 
	1.3.3 Bulking Agents 
	1.3.4 Sacral Nerve Stimulation Implantable Neurostimulation Percutaneous Tibial Nerve Stimulation 
	1.3.5 Urethral Slings 
	1.3.6 Surgical Options 

Exhibit 1-1: Urinary Voiding and Afferent Signaling 
Exhibit 1-2: Sacral Neuromodulation with an Implanted Electrical Stimulator 


2.1 Selected Products 
	2.1.1 Contigen 
	2.1.2 Coaptite 
	2.1.3 Durasphere EXP 
	2.1.4 Macroplastique 
	2.1.5 Bulkamid 
2.2 Market Analysis 
	2.2.1 Procedure Volumes 
	2.2.2 Market Forecast 
	2.2.3 Competitive Analysis 

Exhibit 2-1: The Coaptite Injectable Implant Procedure 
Exhibit 2-2: The Macroplastique Urethral Bulking Agent 
Exhibit 2-3: Macroplastique Treatment, Key Efficacy Results at 12 Months 
Exhibit 2-4: Macroplastique Treatment, Key Adverse Events 
Exhibit 2-5: Minimally Invasive Urethral Bulking Agent Therapy,  Procedure Volumes Forecast, 2010-2015 
Exhibit 2-6: Minimally Invasive Urethral Bulking Agents, Market Forecast, 2010-2015 
Exhibit 2-7: 2010, Minimally Invasive Urethral Bulking Agents Market, Share by Supplier 


3.1 Selected Products 
	3.1.1 American Medical Systems/Endo Pharmaceuticals Urethral Slings for Women Urethral Slings for Men 
	3.1.2 Bard Medical/C.R. Bard 
	3.1.3 Boston Scientific 
	3.1.4 Caldera Medical 
	3.1.5 Coloplast 
	3.1.6 Cook Medical/Cook Group 
	3.1.7 Ethicon/Johnson & Johnson 
	3.1.8 Promedon 
3.2 Market Analysis 
	3.2.1 Procedure Volumes 
	3.2.2 Market Forecast 
	3.2.3 Competitive Analysis 

Exhibit 3-1: 2011, Selected Urethral Sling Systems 
Exhibit 3-2: The MiniArc Precise Single-Incision Sling System 
Exhibit 3-3: The MiniArc Single-Incision Sling 
Exhibit 3-4: The Monarc Subfascial Hammock 
Exhibit 3-5: Suprapubic and Transobturator Approaches to Mid-Urethral Sling Placement Using the BioArc SP and BioArc TO Sling Systems 
Exhibit 3-6: 12-Step Mid-Urethral Sling Implant Procedure Using the BioArc SP Sling System 
Exhibit 3-7: The In-Fast Ultra Transvaginal Sling 
Exhibit 3-8: The Ajust Adjustable Single-Incision Sling 
Exhibit 3-9: The Align Urethral Support System 
Exhibit 3-10: The PelviLace Biourethral Support System 
Exhibit 3-11: The Advantage Fit System 
Exhibit 3-12: Components of the Advantage Transvaginal Mid-Urethral Sling System 
Exhibit 3-13: Steps in a Mid-Urethral Sling Implant Procedure Using the Advantage Sling System 
Exhibit 3-14: The Desara Sling System 
Exhibit 3-15: Mesh Integrity, Comparison of the Desara Mesh with Other Slings 
Exhibit 3-16: The Aris Transobturator Sling System 
Exhibit 3-17: The Biodesign Tension-Free Urethral Sling 
Exhibit 3-18: The TVT ABBREVO Continence System 
Exhibit 3-19: Safety Advantages of the TVT ABBREVO Procedure 
Exhibit 3-20: Comparable Clinical Improvement at 12 months, Modified TVT Obturator System versus the Unaltered TVT Obturator System 
Exhibit 3-21: TVT Tension-Free Support for Incontinence and TVT EXACT Continence Systems, Comparative Perforation and Voiding Dysfunction Rates 
Exhibit 3-22: Comparative Benefits of the TVT SECUR Mini Single-Incision Sling as Compared with the MiniArc Sling System 
Exhibit 3-23: The Ophira Mini Sling System 
Exhibit 3-24: The Argus Adjustable Male Sling System 
Exhibit 3-25: Minimally Invasive Urethral Sling Implantation, Procedure Volumes Forecast, 2010-2015 
Exhibit 3-26: Minimally Invasive Urethral Sling Systems, Market Forecast, 2010-2015 
Exhibit 3-27: 2010, Minimally Invasive Urethral Sling Systems Market, Share by Supplier 


4.1 Selected Products 
	4.1.1 InterStim Therapy System 
	4.1.2 Urgent PC Neuromodulation System 
4.2 Market Analysis 

Exhibit 4-1: The InterStim Therapy System 
Exhibit 4-2: InterStim Therapy, 12-Month and 5-Year Sustained Clinical Efficacy 
Exhibit 4-3: The Sacral Plexus 
Exhibit 4-4: The Urgent PC Neuromodulation System 
Exhibit 4-5: Summary of a Meta-Analysis of Percutaneous Tibial Nerve Stimulation Using the Urgent PC Neuromodulation System 


5.1 Selected Products 
	5.1.1 Renessa System 
	5.1.2 NeoControl Pelvic Floor Therapy System 
	5.1.3 MS-106 Twin and MS-310 Pelvic Floor Stimulators 
	5.1.4 Liberty System 

Exhibit 5-1: The Renessa System and Benefits of Treatment 
Exhibit 5-2: Renessa Therapy's Place in the Spectrum of Treatment Options 
Exhibit 5-3: The Renessa Procedure and Mechanism of Action 
Exhibit 5-4: NeoControl Pelvic Floor Therapy and Mechanism of Action 
Exhibit 5-5: The MS-106 Twin and MS-310 Pelvic Floor Stimulators 
Exhibit 5-6: Liberty System Pelvic Floor Stimulator 


6.1 American Medical Systems, Inc./Endo Pharmaceuticals Holdings, Inc. 
6.2 C.R. Bard, Inc. 
6.3 Boston Scientific Corporation 
6.4 Caldera Medical, Inc. 
6.5 Coloplast AS 
6.6 Contura International AS/Idosan AS 
6.7 Cook Group, Inc. 
6.8 Johnson & Johnson 
6.9 Medtronic, Inc. 
6.10 Uroplasty, Inc. 



  1. American Medical Systems, Inc./Endo Pharmaceuticals Holdings, Inc.
  2. C.R. Bard, Inc.
  3. Boston Scientific Corporation
  4. Caldera Medical, Inc.
  5. Coloplast AS
  6. Contura International AS/Idosan AS
  7. Cook Group, Inc.
  8. Johnson & Johnson
  9. Medtronic, Inc.
  10. Uroplasty, Inc.
Contact Us

Need help finding medtech research? Let us help you!